Navigation Links
Biopharma in Medical News

PDL BioPharma Elects Barry Selick to Its Board of Directors

INCLINE VILLAGE, Nev., Aug. 3 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced the appointment of Harold E. ("Barry") Selick, Ph.D., to the Company's Board of Directors. "Barry's experience as a seasoned biotechnology executive and his extensiv...

PDL BioPharma Announces Second Quarter 2009 Financial Results

INCLINE VILLAGE, Nev., July 30 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today reported financial results for the second quarter ended June 30, 2009. Total revenues from continuing operations for the second quarter of 2009 were $125.9 million,...

PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009

INCLINE VILLAGE, Nev., July 22 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that the company will hold a conference call and webcast on Thursday, July 30 at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter of 200...

DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller

PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it recently appointed Christopher P. Schnittker, CPA as its new Vice President of Administration and Controller. In th...

AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium

GAI-122, an investigational injectable nanoemulsion formulated with AlphaRx's proprietary drug delivery technology, providing significant neuro-protection in multiple in vitro and in vivo studies which suggest that this injectable nanoemulsion formulation has the potential to ...

Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF

AURORA, Ontario, June 23 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP; OTCQX: HXBPF) announced today that it has commenced trading in the U.S. on the OTCQX International Market under the ticker symbol HXBPF. Investors can find real-time quotes, disclosure and financial informati...

AlphaRx and Gaia BioPharma Provide GAI-122 Development Update

GAI-122, an investigational injectable nano-emulsion formulated with AlphaRx's proprietary drug delivery technology, provides significant neuroprotection in animal behavioral models. Gaia BioPharma plans to initiate a clinical development program to further study GAI-122 for an ...

PDL BioPharma Announces Record Date for October 1 Dividend Payment

INCLINE VILLAGE, Nev., June 10 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that all shareholders owning shares of PDL on September 17, 2009, will be paid a dividend of $0.50 per share on October 1, 2009. The Company previously announced that it would pay t...

The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate

CLINTON, N.J., May 27 /PRNewswire/ -- The Sage Group, a privately held international health care consulting group, announced today that HemispherX Biopharma has expanded the mandate for The Sage Group to include, in addition to the strategic partnering efforts related to Ampligen (an experimental ...

PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer

- Company Updates Board of Directors Audit Committee Members and Complies with Nasdaq Rule - INCLINE VILLAGE, Nev., April 29 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that its board of directors has appointed Karen J. Wilson as vice president of fin...
Biopharma in Medical Technology

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

--Orally Active Enhancer of Human Nerve Growth Factor Has Demonstrated Promising Activity Preclinically-- --Broad Potential Applications Include Neuropathies, Alzheimer's and Huntington's Disease and Others-- RESEARCH TRIANGLE PARK, N.C., June 16 /PRNewswire/ -- CeNeRx BioPharma, Inc., a...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmato...

Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.

SUNNYVALE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Pharmacyclics (Nasdaq: PCYC ) announced today the close of a financing in connection with an investment by the principals of Pacific Biopharma Group, Ltd. (PBG), located in San Bruno California and Taizhou, Jiangsu Province, People's Republi...

Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand

NEWARK, Del., Dec. 3 /PRNewswire/ -- Isogen, a contract development and manufacturing organization for sterile filling, announced it has retained a strategic financial partner to help it expand operations to meet the global biopharma demand for Isogen's services. Isogen has previously anno...

Isogen Launches Major New Facility to Address Global Biopharma Demand

NEWARK, Del., Nov. 19 /PRNewswire/ -- Isogen, a contract development and manufacturing organization for sterile filling, today announced the first phase launch of its contract facility in Delaware. Isogen was founded to specifically address the process, facility and capacity problems commonly asso...

CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)

RESEARCH TRIANGLE PARK, N.C., Oct. 17 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced that it has initiated a Phase II clinical trial for its lead product candidate...

CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study

- State-of-the-Art PET Study Confirms Tyrima Exhibits Excellent Drug-Like Properties - - Results Support Initiation of Phase II Clinical Trials - RESEARCH TRIANGLE PARK, N.C., July 22 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing ...

Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation

LOS ANGELES, California, June 18 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer and addiction, today announced the signing of ...

CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)

- Tyrima Exhibits Excellent Safety Profile and Favorable Pharmacokinetics in Phase I Studies - RESEARCH TRIANGLE PARK, N.C., Jan. 16 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the...

Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN 918864) AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Research at Helix BioPharma Corp., a developer of novel cancer therapeutics, will be presenting a scientific poster at the Fourth International Conference on Tumor Microenvi...

More>>

Biopharma in Biological News

Biodegradable polymers show promise for improving treatment of acute inflammatory diseases

... and Robert Pierce, currently head of anatomic pathology at Schering-Plough biopharma Schering-Plough biopharma and formerly of the University of Rochester Medical Center, are collaborati...

OHSU turns innovations into commercial opportunities at record pace

...formation about Molecular MD, go to http://www.molecularmd.com ] ID biopharma which was spun off by Virogenomics Inc., an earlier OHSU startup -- was c...hnology and pharmaceutical companies in focusing on infectious diseases. ID biopharma will function as the commercialization accelerator for the Oregon Translati...

Intelligent materials to regenerate bone tissue

...nerate in such a way that it carries out similar functions as in its natural state. From Spain the Institute of Biomechanics of Valencia and Progénika biopharma S.A. are also participating. In the case of substantial deterioration of the bone, it may be necessary for the implant to provide both functional...

Ocean virus identified in human blood samples

...ys available to test for Vesivirus infection or antibodies, researchers say, that have been developed at OSU and licensed to private industry. "AVI biopharma has investigated their proprietary NeuGene antisense as an anti-Vesiviral treatment, and is currently conducting further research and development," sa...

Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned

... the United States and Europe. The CDC classifies ricin as a "Category B" biological agent, which means it is "relatively easy to disseminate." DOR biopharma has received an exclusive license for RiVax and is developing large scale manufacturing processes. DOR officials hope to produce a large stockpile for...
Biopharma in Biological Technology

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

PRINCETON, N.J., Aug. 4 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Or...

PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009

INCLINE VILLAGE, Nev., July 29 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the BMO Capital Markets Healthcare Conference in New York City on Wednes...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it has received a European patent which addresses its Lipid Polymer Micelle (LPM(TM)) technology for the improved oral...

Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease

EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of can...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

PRINCETON, N.J., June 29 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that investigators at the Fred Hutchinson Cancer Research Center, Seattle, Washington, published a paper this morning...

KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)

DURHAM, N.C., June 24 /PRNewswire/ -- KBI Biopharma, Inc. (KBI) announced today that it has started the process of performing cell line generation with Crucell's PER.C6(R) human cell line platform, pursuant to the Agreement announced by Crucell, The Netherlands, on May 6, 2009. Under that agreemen...

Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference

AURORA, Ontario, June 19 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP) today announced that Dr. Heman Chao, chief scientific officer at Helix BioPharma Corp., will be presenting a scientific poster describing L-DOS47 analytical method development findings at the 2009 American Ass...

Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy

TROMS0, Norway and SEOUL, Korea, June 19 /PRNewswire/ -- The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced the signing of a collaborative agreement to test lead compounds LTX-315 and GV1001 as a combination therapy for the treatment of cance...

Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.

FORT WORTH, Texas, June 16 /PRNewswire/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (WNDM.OB), announced today that it has reached an agreement in principle to acquire BioPharma Management Technologies, Inc., a privately held biotechnology company with a pl...

Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update

AURORA, Ontario, June 15 /PRNewswire/ -- Helix BioPharma Corp. ("Helix" or the "Company"), (TSX, FSE: "HBP") today announced its product development progress, quarterly highlights and financial results for the third quarter of fiscal 2009, ended April 30, 2009. THIRD QUARTER HIGHLIGHTS AND P...
Biopharma in Biological Products

ELISA Biopharma from Tecan

Description: Tecan has 20 years of expertise in the field of Enzyme-Linked Immunosorbent Assays (ELISA), and still offers the most powerful systems on the market. Freedom EVO easily manages up to 40 000 in-microplate tests requiring incubation and washing steps. The integration of different modules (such as w...
Company:Tecan
Other Tags
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ... of the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major ... demand for medical sensors in biomedical applications. Chemical ... quick and correct diagnosis during surgical procedures. The ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
Other Contents